Abstract
Insomnia is a significant public health concern that has prompted substantial efforts to develop treatment and management strategies. A significant proportion of complaints of insomnia are related to psychiatric conditions such as anxiety disorders and depression, and treatments for these disorders are known to exert both direct and indirect benefits on sleep as well as some negative effects on sleep and sleep physiology. Insomnia is also a prominent symptom of a number of other psychiatric disorders, including schizophrenia and bipolar disorder. The observed impact of a variety of psychiatric medications on insomnia has prompted an empirically derived practice of treating non-psychiatric disorder-related insomnia with psychiatric medications by clinicians searching for alternatives to established medication treatments for primary insomnia. This article aims to review the evidence of the impact of psychiatric medications on sleep physiology, sleep disorders in psychiatric conditions, and on primary sleep disorders. The potential for exploiting the relevant pharmacological mechanisms of action in drug development for primary insomnia will be addressed as well.
Keywords: Insomnia, antidepressants, antipsychotics, anticonvulsants, psychiatry, drug development
CNS & Neurological Disorders - Drug Targets
Title: Effects of Psychiatric Medications on Sleep and Sleep Disorders
Volume: 6 Issue: 1
Author(s): Nicholas A. DeMartinis and Andrew Winokur
Affiliation:
Keywords: Insomnia, antidepressants, antipsychotics, anticonvulsants, psychiatry, drug development
Abstract: Insomnia is a significant public health concern that has prompted substantial efforts to develop treatment and management strategies. A significant proportion of complaints of insomnia are related to psychiatric conditions such as anxiety disorders and depression, and treatments for these disorders are known to exert both direct and indirect benefits on sleep as well as some negative effects on sleep and sleep physiology. Insomnia is also a prominent symptom of a number of other psychiatric disorders, including schizophrenia and bipolar disorder. The observed impact of a variety of psychiatric medications on insomnia has prompted an empirically derived practice of treating non-psychiatric disorder-related insomnia with psychiatric medications by clinicians searching for alternatives to established medication treatments for primary insomnia. This article aims to review the evidence of the impact of psychiatric medications on sleep physiology, sleep disorders in psychiatric conditions, and on primary sleep disorders. The potential for exploiting the relevant pharmacological mechanisms of action in drug development for primary insomnia will be addressed as well.
Export Options
About this article
Cite this article as:
DeMartinis A. Nicholas and Winokur Andrew, Effects of Psychiatric Medications on Sleep and Sleep Disorders, CNS & Neurological Disorders - Drug Targets 2007; 6 (1) . https://dx.doi.org/10.2174/187152707779940835
DOI https://dx.doi.org/10.2174/187152707779940835 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Genetics and Biomarkers of Polyglutamine Diseases
Current Molecular Medicine Pharmacophore Modeling, 3D-QSAR and Molecular Docking of Furanochalcones as Inhibitors of Monoamine Oxidase-B
Central Nervous System Agents in Medicinal Chemistry Current Role of Proteomics in Pancreatic Cancer Biomarkers Research
Current Proteomics The Mitochondrial Cascade Hypothesis for Parkinsons Disease
Current Pharmaceutical Design [1, 2, 4]-Oxadiazoles: Synthesis and Biological Applications
Mini-Reviews in Medicinal Chemistry Subject Index To Volume-3
Letters in Drug Design & Discovery Editorial (Thematic Issue: Translational Perspectives in Treatment-Resistant Mood Disorders)
Current Neuropharmacology Molecular Docking Studies of Flavonoids Derivatives on the Flavonoid 3- O-Glucosyltransferase
Current Computer-Aided Drug Design <i>Propionibacterium acnes</i> in the Pathogenesis and Immunotherapy of Acne Vulgaris
Current Drug Metabolism Editorial
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Reprogramming of B Cells into Regulatory Cells with Engineered Fusokines
Infectious Disorders - Drug Targets Abnormalities in Kynurenine Pathway Metabolism in Treatment-Resistant Depression and Suicidality: A Systematic Review
CNS & Neurological Disorders - Drug Targets Postmortem-Assessed Impairment of Neuronal Activity in Depression: The Dominant Impact of Suicide
CNS & Neurological Disorders - Drug Targets The Role of Melatonin in Rheumatic Diseases
Infectious Disorders - Drug Targets Development of Polymeric Prodrugs as a Therapeutic Agent for Alzheimers Disease by Mechanochemical Solid-State Polymerization
Current Medicinal Chemistry - Central Nervous System Agents Priority Strategies for Sustainable Fight Against HIV/AIDS in Low-Income Countries
Current HIV Research Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Development, Recent Achievements and Current Directions of Research into GABA Uptake Inhibitors
Current Medicinal Chemistry Modulatory Effects of pH, Cu+2 and Sheet Breakers on Aggregation of Amyloid Peptides
Protein & Peptide Letters Antiviral Sensing in Teleost Fish
Current Pharmaceutical Design